DNA Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1830214 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-33.1%
TTM net income YoY26.1%
TTM EPS YoY—
Revenue 3-yr CAGR-31.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-242.5%
Net margin-249.2%
FCF margin-172.3%
EBITDA margin-190.5%
Returns
ROE-52.7%
ROA-23.5%
ROIC (approx.)-51.0%
Asset turnover0.09x
Leverage & solvency
Liabilities / assets58.4%
Debt / equity0.00x
Current ratio4.72x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue6.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $27.71M | $20.16M | $19.47M | $33.40M | $29.38M | $39.13M | $38.23M | $43.85M |
| Cost of revenue | $1.81M | $1.72M | $3.10M | — | $4.62M | $5.38M | $4.09M | — |
| Gross profit | $25.91M | $18.44M | $16.38M | — | $24.75M | $33.75M | $34.14M | — |
| R&D expense | $40.95M | $46.21M | $49.92M | $50.13M | $69.35M | $53.37M | $70.92M | $76.38M |
| SG&A expense | $28.59M | $30.77M | $37.83M | $46.01M | $36.99M | $34.98M | $39.72M | $57.30M |
| Operating income | -$43.63M | -$58.55M | -$71.37M | -$70.75M | -$82.31M | -$58.16M | -$80.97M | -$103.61M |
| Interest expense | — | — | — | — | — | — | — | $31.37M |
| Pretax income | -$41.26M | -$57.19M | -$76.14M | -$103.55M | -$73.35M | -$53.48M | -$83.22M | -$107.86M |
| Income tax | -$271,000 | $128,000 | -$80,000 | -$643,000 | $1,000 | -$283,000 | $88,000 | -$325,000 |
| Net income | -$40.98M | -$46.71M | -$82.59M | -$80.75M | -$80.75M | -$60.30M | -$90.96M | -$107.53M |
| EBITDA | -$31.59M | -$46.23M | -$58.58M | -$55.46M | -$68.68M | -$42.91M | -$66.15M | -$87.95M |
| EPS (basic) | -0.64 | -0.75 | -1.39 | — | -1.45 | -1.10 | -1.68 | — |
| EPS (diluted) | — | — | — | — | -1.45 | -1.10 | -1.68 | — |
| Weighted avg. shares (diluted) | — | — | — | — | 55.63M | 54.86M | 54.24M | — |
| Banking | ||||||||
| Net interest income | $3.06M | $3.23M | $3.60M | — | $5.74M | $6.08M | $6.08M | — |
| Loans, net | $7.50M | $7.50M | $7.50M | $9.70M | $22.00M | $22.00M | $24.90M | $25.10M |
| Balance sheet | ||||||||
| Cash & equivalents | $84.50M | $84.53M | $143.86M | $167.20M | $111.06M | $203.57M | $312.42M | $561.57M |
| Short-term investments | — | — | — | $255.42M | $384.42M | $355.79M | $12.84M | $0 |
| Receivables | $11.48M | $13.01M | $19.82M | $24.03M | $21.43M | $22.15M | $26.29M | $21.86M |
| Current assets | $310.84M | $332.54M | $409.95M | $471.84M | $506.08M | $523.02M | $564.53M | $602.74M |
| PP&E, net | $152.35M | $157.19M | $163.02M | $167.37M | $176.58M | $186.35M | $197.83M | $203.72M |
| Goodwill | — | — | — | — | — | — | — | $0 |
| Intangibles | $39.73M | $44.39M | $48.86M | $53.48M | $61.52M | $66.15M | $68.76M | $72.51M |
| Total assets | $944.45M | $990.05M | $1.03B | $1.12B | $1.19B | $1.23B | $1.29B | $1.38B |
| Current liabilities | $65.85M | $72.74M | $79.59M | $95.97M | $115.28M | $96.72M | $115.67M | $107.27M |
| Total liabilities | $551.82M | $569.76M | $589.92M | $611.11M | $629.38M | $618.06M | $646.04M | $661.39M |
| Shareholders' equity | $392.64M | $420.28M | $443.15M | $508.59M | $559.78M | $612.95M | $647.43M | $716.06M |
| Shares outstanding | 64.50M | 63.71M | 61.66M | 58.21M | 56.84M | 55.43M | 54.70M | 54.37M |
| Cash flow statement | ||||||||
| Operating cash flow | -$28.35M | -$44.27M | -$46.69M | -$47.68M | -$31.61M | -$40.25M | -$51.52M | -$42.44M |
| Capital expenditure | $2.00M | $2.62M | $1.93M | $5,000 | $0 | $38,000 | $7.62M | $13.71M |
| Free cash flow | -$30.35M | -$46.89M | -$48.62M | -$47.68M | -$31.61M | -$40.29M | -$59.14M | -$56.15M |
| Investing cash flow | -$24.10M | $11.09M | $23.13M | $95.10M | -$72.82M | -$63.89M | -$198.68M | -$13.09M |
| Financing cash flow | $6.50M | $16.49M | -$19,000 | $8.14M | $9.94M | -$98,000 | -$207,000 | -$203,000 |
| Depreciation & amortization | $12.04M | $12.31M | $12.80M | $15.29M | $13.62M | $15.25M | $14.82M | $15.65M |
| Stock-based compensation | $7.67M | $7.59M | $15.85M | $21.03M | $15.04M | $18.80M | $17.39M | $20.56M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.